Fett introduces DHEA as a potential aid for readers with diminished ovarian reserve or age-related infertility, situating it within the broader concern of how declining hormone precursors affect egg quality. She grounds the discussion in the story of a patient at the Center for Human Reproduction whose self-directed use of DHEA transformed her IVF outcomes, highlighting how patient-driven inquiry can sometimes drive clinical innovation. This anecdote is supported by controlled studies showing that DHEA supplementation, particularly over several months, may improve follicle recruitment, embryo viability, and even natural conception rates in some individuals. Fett also notes that evidence for pregnancy loss reduction is suggestive, with some data linking DHEA to lower chromosomal abnormalities, though findings remain mixed.

She emphasizes that DHEA is most effective when used to correct low hormone levels; it can harm fertility if supplementation pushes levels too high. She points to lab testing for DHEA-S and testosterone as essential for tailoring supplementation, underscoring that indiscriminate or late use may undermine results. Evidence is drawn from clinical trials, meta-analyses, and case reports, which together show both promise and variability in outcomes.

The analysis reveals key assumptions: Fett writes from a biomedical framework that presumes access to hormone testing, fertility clinics, and long-term supplementation, resources not equally available to all. This focus implicitly centers patients in higher-income, medically resourced contexts. Nonetheless, the chapter’s contribution lies in its alignment with ongoing debates in reproductive endocrinology, where mitochondrial health, hormone precursors, and age-related decline remain central research concerns. By framing DHEA as both an experimental and patient-driven intervention, Fett highlights the tension between personalized dosing and the risks of self-supplementation without oversight.

Chapter Lessons

• DHEA supplementation may improve egg numbers, embryo quality, and pregnancy chances, particularly in those with diminished ovarian reserve.
• The benefits of DHEA depend on correcting a deficiency; both too little and too much can impair fertility outcomes.
• Lab testing for DHEA-S and testosterone is essential before and during supplementation to ensure safe, effective dosing.
• While promising, DHEA is not universally suitable and requires medical guidance, especially for those with hormone-sensitive conditions or high testosterone.

Reflection Questions

• How does learning that DHEA can both help and harm depending on your hormone levels change the way you think about supplementing without medical guidance?
• If you were faced with the uncertainty of diminished ovarian reserve, how would you weigh the hope offered by DHEA against the need for careful monitoring and medical oversight?

Fett shifts focus from promising fertility aids to supplements that sound compelling but lack meaningful evidence, or worse, pose risks. She argues that while antioxidants like CoQ10 or melatonin align with natural cellular biology, others, such as resveratrol, turmeric, vitex, maca, pycnogenol, royal jelly, and high-dose L-arginine, fall short of that standard. The common thread is marketing appeal unsupported by strong clinical outcomes.

Fett supports this caution with targeted studies. For instance, resveratrol, though associated with mitochondrial health, has been linked to impaired endometrial receptivity and higher pregnancy loss rates. Turmeric and curcumin, valued for anti-inflammatory effects, may disrupt estrogen signaling and damage uterine lining development. Similarly, vitex and royal jelly come from longstanding traditional or folk practices but have little modern safety data, and in some cases show harmful hormonal effects or allergic risks. Maca raises further concerns because of heavy-metal contamination in growing regions, while L-arginine shows dose-dependent contradictions: Modest intake may support blood flow, but high doses impair egg and embryo development.

This chapter illustrates Fett’s broader argument that “natural” does not equal “safe” or “effective.” By contrasting popular but unproven options with supplements rooted in ovarian biology, she underscores the importance of aligning fertility choices with scientific evidence rather than anecdote or marketing. Her approach resonates in a cultural context where the wellness industry often thrives on uncertainty, offering hope in the form of pills and powders with minimal oversight.

At the same time, the guidance presumes that readers have both access to reliable medical information and the confidence to reject alluring but risky alternatives. That expectation may not reflect the reality of all fertility journeys, especially where desperation or inequities in healthcare access shape decisions. Even so, Fett’s stance reframes caution as empowerment, suggesting that avoiding certain interventions can be just as vital to reproductive health as pursuing proven ones.

Chapter Lessons

• Supplements with marketing appeal but little biological relevance, like resveratrol, turmeric, or maca, may harm rather than help fertility.
• Traditional remedies such as vitex and royal jelly lack reliable safety data and can disrupt hormonal balance or trigger allergic reactions.
• ”Natural” does not automatically equal “safe” or “effective”; evidence-backed supplements should be prioritized over anecdote or tradition.
• Exercising caution and resisting unproven remedies is itself an active strategy for protecting reproductive health.

Reflection Questions

• How does learning that some widely praised supplements may actually harm fertility change the way you think about the promise of the wellness industry?
• When faced with so many supplement options, what helps you decide which advice to trust and which to question?